Divisions of Pulmonary, Critical Care and Sleep Medicine University of Texas Health- McGovern Medical School, TX, 77030, USA.
Department of Internal Medicine University of Texas Health- McGovern Medical School, TX, 77030, USA.
Respir Med. 2020 Nov;173:106153. doi: 10.1016/j.rmed.2020.106153. Epub 2020 Sep 20.
Since March 2019, E-cigarette or Vaping product associated lung injury (EVALI) has become an ongoing epidemic with more 2600 cases reported in the span of a few months in the United States. EVALI is defined as acute lung injury that develops secondary to the use of e-cigarettes or vaping products within the previous 90 days after exlusion of other possible inciting factors. Vitamin E acetate is believed to play a significant role in its pathogenesis. Treatment involves use of corticosteroids and further avoidance of these products. We describe a case series of 8 patients with EVALI, their clinical course and outcomes. All patients showed an excellent response to corticosteroids. In our experience, prognosis of EVALI is excellent, with complete resolution of symptoms in patients who followed up at 8 weeks.
自 2019 年 3 月以来，电子烟或蒸气烟相关肺损伤（EVALI）已成为一场持续的流行疾病，在美国短短几个月内报告了超过 2600 例病例。EVALI 的定义为在排除其他可能引发因素后的 90 天内，因使用电子烟或蒸气烟产品而导致的急性肺损伤。维生素 E 醋酸盐被认为在其发病机制中起重要作用。治疗方法包括使用皮质类固醇，并进一步避免使用这些产品。我们描述了 8 例 EVALI 患者的病例系列，包括他们的临床过程和结果。所有患者对皮质类固醇均有极好的反应。根据我们的经验，EVALI 的预后极好，在 8 周时随访的患者症状完全缓解。
